These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34061524)

  • 1. Investigating the Influence of Excipients on the Stability of Levothyroxine Sodium Pentahydrate.
    Kaur N; Suryanarayanan R
    Mol Pharm; 2021 Jul; 18(7):2683-2693. PubMed ID: 34061524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial Dehydration of Levothyroxine Sodium Pentahydrate in a Drug Product Environment: Structural Insights into Stability.
    Kaur N; Young VG; Su Y; Suryanarayanan R
    Mol Pharm; 2020 Oct; 17(10):3915-3929. PubMed ID: 32960611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levothyroxine Sodium Pentahydrate Tablets - Formulation Considerations.
    Kaur N; Suryanarayanan R
    J Pharm Sci; 2021 Dec; 110(12):3743-3756. PubMed ID: 34384799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets.
    Patel H; Stalcup A; Dansereau R; Sakr A
    Int J Pharm; 2003 Oct; 264(1-2):35-43. PubMed ID: 12972334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in Transitioning Cocrystals from Bench to Bedside: Dissociation in Prototype Drug Product Environment.
    Koranne S; Sahoo A; Krzyzaniak JF; Luthra S; Arora KK; Suryanarayanan R
    Mol Pharm; 2018 Aug; 15(8):3297-3307. PubMed ID: 29947519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.
    Collier JW; Shah RB; Gupta A; Sayeed V; Habib MJ; Khan MA
    AAPS PharmSciTech; 2010 Jun; 11(2):818-25. PubMed ID: 20454876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Microenvironmental Acidity: A Strategy to Mitigate Salt Disproportionation in Drug Product Environment.
    Koranne S; Lalge R; Suryanarayanan R
    Mol Pharm; 2020 Apr; 17(4):1324-1334. PubMed ID: 32142293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of Spatial Heterogeneity of Salt Disproportionation in Tablets by Synchrotron X-ray Diffractometry.
    Koranne S; Govindarajan R; Suryanarayanan R
    Mol Pharm; 2017 Apr; 14(4):1133-1144. PubMed ID: 28195490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation about wettability, water absorption or swelling of excipients through various methods and the correlation between these parameters and tablet disintegration.
    Yang B; Wei C; Yang Y; Wang Q; Li S
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1417-1425. PubMed ID: 29557692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface acidity and solid-state compatibility of excipients with an acid-sensitive API: case study of atorvastatin calcium.
    Govindarajan R; Landis M; Hancock B; Gatlin LA; Suryanarayanan R; Shalaev EY
    AAPS PharmSciTech; 2015 Apr; 16(2):354-63. PubMed ID: 25319055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Excipients on Salt Disproportionation during Dissolution: A Novel Application of In Situ Raman Imaging.
    Abouselo A; Rance GA; Tres F; Taylor LS; Kwokal A; Renou L; Scurr DJ; Burley JC; Aylott JW
    Mol Pharm; 2021 Sep; 18(9):3247-3259. PubMed ID: 34399050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulating weakly basic HCl salts: relative ability of common excipients to induce disproportionation and the unique deleterious effects of magnesium stearate.
    John CT; Xu W; Lupton LK; Harmon PA
    Pharm Res; 2013 Jun; 30(6):1628-41. PubMed ID: 23512680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Metallic Stearates on Disproportionation of Hydrochloride Salts of Weak Bases in Solid-State Formulations.
    Nie H; Xu W; Ren J; Taylor LS; Marsac PJ; John CT; Byrn SR
    Mol Pharm; 2016 Oct; 13(10):3541-3552. PubMed ID: 27542728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of drug-excipient interaction in the formulation of celecoxib tablets.
    Bozdağ-Pehlivan S; Subaşi B; Vural I; Unlü N; Capan Y
    Acta Pol Pharm; 2011; 68(3):423-33. PubMed ID: 21648198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved blend and tablet properties of fine pharmaceutical powders via dry particle coating.
    Huang Z; Scicolone JV; Han X; Davé RN
    Int J Pharm; 2015 Jan; 478(2):447-55. PubMed ID: 25475016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions.
    Svirskis D; Lin SW; Brown H; Sangaroomthong A; Shin D; Wang Z; Xu H; Dean R; Vareed P; Jensen M; Wu Z
    Int J Pharm Compd; 2018; 22(2):164-171. PubMed ID: 29877863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical stability of crystal hydrates and their anhydrates in the presence of excipients.
    Salameh AK; Taylor LS
    J Pharm Sci; 2006 Feb; 95(2):446-61. PubMed ID: 16380975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The solution and solid state stability and excipient compatibility of parthenolide in feverfew.
    Jin P; Madieh S; Augsburger LL
    AAPS PharmSciTech; 2007 Dec; 8(4):E105. PubMed ID: 18181526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Insights on Solid-State Changes in the Levothyroxine Sodium Pentahydrate during Dehydration and its Relationship to Chemical Instability.
    Shah HS; Chaturvedi K; Hamad M; Bates S; Hussain A; Morris K
    AAPS PharmSciTech; 2019 Jan; 20(1):39. PubMed ID: 30604134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of excipient properties, water activity, and water content on the disproportionation of a pharmaceutical salt.
    Patel MA; Luthra S; Shamblin SL; Arora KK; Krzyzaniak JF; Taylor LS
    Int J Pharm; 2018 Jul; 546(1-2):226-234. PubMed ID: 29772284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.